- Prevalence of pulmonary embolism in patients with obstructive sleep apnea and chronic obstructive pulmonary disease: The overlap syndrome. [Journal Article]
- HLHeart Lung 2018 Nov 26
- CONCLUSIONS: OS is independently associated with PE prevalence. Longitudinal studies are needed to better understand the relationship with incident PE.
- Freedom from chronic lung allograft dysfunction (CLAD) or CLAD-free survival: What's in a name? [Editorial]
- JHJ Heart Lung Transplant 2018 Nov 15
- Seven days in medicine: 21-27 November 2018. [Journal Article]
- BMJBMJ 2018 Nov 29; 363:k5007
- GPs order three times as many diagnostic tests as 15 years ago, study finds. [Journal Article]
- BMJBMJ 2018 Nov 29; 363:k5093
- Need for international classification of gabapentin as a controlled substance. [Letter]
- BMJBMJ 2018 Nov 29; 363:k4978
- Rethinking community based strategies to tackle health inequities in South Asia. [Journal Article]
- BMJBMJ 2018 Nov 29; 363:k4884
- Rituximab in neurological disease: principles, evidence and practice. [Journal Article]
- PNPract Neurol 2018 Nov 29
- Rituximab is a widely used B-cell-depleting monoclonal antibody. It is unlicensed for use in neurological disorders and there are no treatment guidelines. However, as a rapidly acting, targeted thera...
Rituximab is a widely used B-cell-depleting monoclonal antibody. It is unlicensed for use in neurological disorders and there are no treatment guidelines. However, as a rapidly acting, targeted therapy with growing evidence of efficacy and tolerability in several neuroinflammatory disorders, it is an attractive alternative to conventional immunomodulatory medications. This practical review aims to explain the basic principles of B-cell depletion with therapeutic monoclonal antibodies. We present the evidence for using rituximab in neurological diseases, and describe the practical aspects of prescribing, including dosing, monitoring, safety, treatment failure and its use in special circumstances such as coexisting viral hepatitis, pregnancy and lactation. We provide an administration guide, checklist and patient information leaflet, which can be adapted for local use. Finally, we review the safety data of rituximab and ocrelizumab (a newer and recently licensed B-cell-depleting therapy for multiple sclerosis) and suggest monitoring and risk reduction strategies.
- HIV post-exposure prophylaxis (PEP). [Journal Article]
- BMJBMJ 2018 Nov 29; 363:k4928
- Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. [Review]
- HSHepatobiliary Surg Nutr 2018; 7(5):353-371
- Hepatocellular carcinoma (HCC) is the sixth-most common cancer and the third leading cause of cancer-related death in the world. However, 40-70% patients eventually suffer from postoperative recurren...
Hepatocellular carcinoma (HCC) is the sixth-most common cancer and the third leading cause of cancer-related death in the world. However, 40-70% patients eventually suffer from postoperative recurrence within 5 years. HCC recurrence after surgery severely affects prognosis of the patients. Nevertheless, there is an opportunity to improve patients' prognosis if doctors and researchers can recognize the importance of a standardized perioperative management and study it in clinical and pre-clinical settings. Hence, based on our own experience and published studies from other researchers, we develop this consensus regarding multidisciplinary management of locally recurrent and metastatic hepatocellular carcinoma after resection. This consensus consists of the entire course of recurrent hepatocellular carcinoma (RHCC) management, including prediction of recurrence, prevention, diagnosis, treatment and surveillance of RHCC. Consensus recommendations are presented with grades of evidences (Ia, Ib, IIa, IIb, III and IV), and strength of recommendations (A, B, C, D and E). We also develop a decision-making path for RHCC treatment, which can intuitively demonstrate the management for RHCC. It is hoped that we may make some effort to standardize the management of RHCC and ultimately understand how to improve outcomes.
Previous New Search Next
- Quality of Life and Mental Health in Older Adults with Obesity and Frailty: Associations with a Weight Loss Intervention. [Journal Article]
- JNJ Nutr Health Aging 2018; 22(10):1259-1265
- CONCLUSIONS: The significant bi-directional associations found between a weight loss intervention and mental health/quality of life, including substantial improvements in physical quality of life with obesity treatment, indicate the importance of considering mental health and quality of life as part of any weight loss intervention for older adults.